Phase I/II Clinical Trial of Autologous Activated Platelet-Rich Plasma (aaPRP) in the Treatment of Severe Coronavirus Disease 2019 (COVID-19) Patients.

Karina KarinaIis RoslianaImam RosadiSiti SobariahLouis Martin ChristoffelRita NovarianiSiti RosidahNovy FatkhurohmanYuli HertatiNurlaela PuspitaningrumWismo Reja SubrotoIrsyah AfiniDifky Ernanda

Published in: International journal of inflammation (2021)

Our results of the phase I/II trial demonstrated that the use of aaPRP in severe COVID-19 patients was safe and not associated with serious adverse events, which showed that aaPRP was a promising adjunctive therapy for severe COVID-19 patients.

Keyphrases

platelet rich plasma
clinical trial
sars cov
coronavirus disease
early onset
study protocol
phase ii
phase iii
randomized controlled trial
open label
bone marrow
respiratory syndrome coronavirus
mesenchymal stem cells
cell therapy
double blind